Canadian Collaborators Launch Medical Cannabis Liver Disease Program
Intermediate magnification micrograph of periportal steatosis of the liver. Credit: Nephron.
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Revive Therapeutics and Ehave have announced that they have entered into a collaboration agreement to enable enhanced patient and clinical research data management for Revive’s research initiatives involving medical cannabis for the treatment of liver diseases.
The collaboration agreement will leverage Ehave’s core expertise in health informatics through its Ehave Connect platform. Revive will integrate the Ehave Connect solution of diagnostic and treatment tools with its ongoing research initiatives in liver disease to improve the lives of patients. Ehave Connect will collect and integrate patient data from clinical systems, licensed health surveys, and Ehave’s own patient- and clinician-reported outcome applications, empowering users with an end-to-end patient management solution, allowing for better treatment decisions across teams and disciplines while keeping patients informed and engaged throughout their healthcare journey.
“We are very excited with our collaboration with Ehave as it provides us with a foundation of employing next generation patient and clinical research data management solutions early on in the research and development phase of our liver disease program,” said Craig Leon, Chief Executive Officer of Revive. “Ehave’s Platform will support our research and clinical decisions and it will allow us to make objective, data-driven decisions throughout the course of our research and may provide unique insights to expand our initiatives with cannabinoids for the potential treatment of liver diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and fibrosis.”
“Our collaboration with Revive is an important step toward realizing Ehave’s broader goal of partnering with the healthcare community, and in particular companies advancing novel medical cannabis products, to facilitate clinical trials and patient management with a single easy-to-use, end-to-end data informatics platform,” stated Prateek Dwivedi, President and CEO of Ehave. “Not only will this collaboration help to streamline Revive’s research and clinical programs, but it also stands to further establish Ehave’s position as a leader in the health informatics space.”